Four of the published sources below describe related problems in biomedical research, each in a different way: Ioannidis (2005) is an essay arguing most findings may be false under common research conditions; Begley & Ellis (Nature, 2012) is a commentary reporting that Amgen confirmed only 6 of 53 deliberately chosen “landmark” cancer papers, and describing a Bayer report of about 25% validated; Freedman, Cockburn & Simcoe (2015) is a perspective estimating $28 billion a year in US preclinical spending that is not reproducible; and Jergas & Baethge (2015) is a pooled analysis of studies of quotation errors in medical journals.
Amgen confirmed only 11% of 53 papers it chose because they described something new, one estimate puts US spending on preclinical work that is not reproducible at about $28 billion a year, and a pooled analysis of studies of medical journals found a total quotation error rate of 25.4% (major errors 11.9%).
These sources measure reproducibility and citation accuracy in research. They do not measure deal diligence directly. Applying that evidence to a specific acquisition target’s citation chain is the gap this service addresses.
| Finding | Source | |
|---|---|---|
| 11% | of 53 “landmark” cancer papers were confirmed in Amgen’s own attempts. The papers were deliberately chosen as describing something new. | Begley & Ellis, Nature, 2012 (a commentary) |
| 20–25% | of Bayer’s 67 in-house target-validation projects had published data completely in line with Bayer’s own findings. | Prinz et al., Nat Rev Drug Discov, 2011, as summarized in open-access reviews; Begley & Ellis give about 25% |
| 25.4% | Total quotation error rate in a pooled analysis of studies of medical journal articles. Major errors, where the cited source does not accord with the claim, were 11.9%; minor errors 11.5%. | Jergas & Baethge, PeerJ, 2015 |
| $28B/yr | Estimated yearly US spend on preclinical research that is not reproducible. | Freedman et al., PLOS Biology, 2015 |
| 31% | of 100 oncology press releases from 8 large pharmaceutical companies (2011 to 2016) included the size of the study findings; 70% reported positive results. | Qunaj et al., JAMA Oncology, 2018 |
| 94% vs 51% | of antidepressant trials looked positive in the published literature, versus in the FDA’s own analysis. | Turner et al., NEJM, 2008 |
| None found | Firms offering a systematized, named citation-chain audit as a service for biotech M&A diligence. | Our review of the firms on the white-space map, April 2026 (not exhaustive) |
The case studies are AbbVie and Stemcentrx, Celgene and mongersen, AbbVie and Cerevel, the CETP inhibitor class and the amyloid hypothesis. Each is built only from company filings, registries and the original papers. They are well-known cases chosen because their records are public, not a sample of all deals. Further cases will be added once every figure and citation in each has been checked against its source.
An independent forensic audit of a biotech target's scientific evidence chain — tracing every citation link behind the mechanism-of-action claim backward to primary sources, checking whether cited studies actually support the claims built on them, and flagging where standard validation is missing. The audit does not run wet-lab experiments, and it covers only public literature, filings and registries, not non-public company data or manufacturing records. It produces an evidence-chain map the acquirer can use to restructure the deal before close, not after — or the investor can use to size the position correctly from the start.